Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
disease, particularly in the context of therapy resistance in colorectal cancer. We are looking for an ambitious cancer biologist to work in Dr Li laboratory who can integrate functional CRISPR screens with
-
, genomics and single-cell molecular analyses, and computational modelling to uncover the principles guiding human embryogenesis. For more information about the laboratory please visit https
-
peuplier, une espèce modèle à croissance rapide et d'une grande importance économique. La thèse utilisera la technologie CRISPR-Cas pour éditer le génome des peupliers et combiner rapidement des allèles
-
HBIGS Heidelberg Biosciences International Graduate School | Heidelberg, Baden W rttemberg | Germany | 23 days ago
, stem cell homeostasis, proliferation and differentiation and is frequently dysregulated in human cancer. In this project you will develop and apply advanced CRISPR genome engineering methods
-
of São Paulo (UNIFESP), in Brazil, aims to investigate how CRISPR-Cas9-mediated genetic modification of Invariant Natural Killer T (iNKT) cells can modulate their antitumor activity and therapeutic
-
endothelial cells, ChIP, immunohistochemistry, cloning, and/or advanced molecular biology techniques (including cloning, lentiviral shRNAi and/or CRISPR/Cas9 in mammalian cells), is mandatory. Experience and
-
, chromatin analysis, single-cell epigenomics). Stem cell research (iPSC culture, differentiation, organoids, neural models). Experience with CRISPR, organoid technology, or mRNA therapeutics is a plus. Proven
-
interests, you will have the opportunity to work with: High‑throughput functional genomics: pooled CRISPR and base‑editing screens, barcoded overexpression libraries, massively parallel reporter assays
-
environment. n line with our and Uni Basel values (https://www.unibas.ch/en/Research/Values-Ethics/Diversity.html ), we are committed to sustain and promote an inclusive culture, ensure equal opportunities and
-
our publications here . Our team is at the forefront of bringing autologous cell replacement therapies with CRISPR-edited muscle stem cells towards the clinic (https://www.mdc-berlin.de/news/news/deep